Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.
Daniel J GeorgeAteesha F MohamedJui-Hua TsaiMilad KarimiNing NingSayeli JayadeMarc BottemanPublished in: Cancer medicine (2022)
Improving OS is the highest priority for patients with mCRPC, but they are willing to trade some survival to reduce the risk of requiring radiation to control bone pain, delay a fracture or bone metastasis, and experience less severe nausea and fatigue.
Keyphrases
- end stage renal disease
- bone mineral density
- ejection fraction
- newly diagnosed
- chronic pain
- squamous cell carcinoma
- chronic kidney disease
- small cell lung cancer
- prognostic factors
- soft tissue
- peritoneal dialysis
- case report
- pain management
- cross sectional
- early onset
- bone loss
- neuropathic pain
- radiation therapy
- depressive symptoms
- spinal cord